(19)
(11) EP 3 391 907 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.03.2020 Bulletin 2020/10

(45) Mention of the grant of the patent:
01.01.2020 Bulletin 2020/01

(21) Application number: 17167295.9

(22) Date of filing: 20.04.2017
(51) International Patent Classification (IPC): 
A61K 45/06(2006.01)
A61K 31/7064(2006.01)
A61K 31/713(2006.01)
A61P 35/02(2006.01)
A61K 38/00(2006.01)
 G01N 33/00(2006.01)
A61K 31/7088(2006.01)
A61P 35/00(2006.01)
A61K 31/00(2006.01)
A61K 38/19(2006.01)

(54)

INTRACELLULAR KINASE SIK3 ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF

MIT RESISTENZ GEGEN KREBSIMMUNANTWORTEN ASSOZIIERTE INTRAZELLULÄRE KINASE SIK3 UND VERWENDUNGEN DAVON

KINASE INTRACELLULAIRE SIK3 ASSOCIÉE À UNE RÉSISTANCE CONTRE DES RÉPONSES IMMUNITAIRES ANTI-TUMEUR ET LEURS UTILISATIONS

(84) Designated Contracting States:
BE CH DE DK FR GB IE LI LU NL SE

(43) Date of publication of application:
24.10.2018 Bulletin 2018/43

(73) Proprietor: iOmx Therapeutics AG
82152 Martinsried (DE)

(72) Inventors:
  • Sorrentino, Antonio
    93051 Regensburg (DE)
  • Beckhove, Philipp
    93059 Regensburg (DE)
  • Michels, Tillmann
    93049 Regensburg (DE)
  • Khandelwal, Nisit
    85152 Martinsried (DE)
  • Boutros, Michael
    67117 Heidelberg (DE)
  • Breinig, Marco
    69198 Schriesheim (DE)
  • Sennhenn, Peter
    85152 Martinsried (DE)
  • Meier-Ewert, Sebastian
    82152 Martinsried (DE)
  • Volpin, Valentina
    93053 Regensburg (DE)
  • Menevse, Ayse
    93049 Regensburg (DE)

(74) Representative: Kuttenkeuler, David 
Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22
80336 München
80336 München (DE)


(56) References cited: : 
WO-A1-2017/043633
 US-A1- 2016 081 989
   
  • JORGE E. CORTES ET AL: "Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib : Third-/fourth-line bosutinib for chronic phase CML", AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, no. 12, 1 December 2016 (2016-12-01), pages 1206-1214, XP055417212, US ISSN: 0361-8609, DOI: 10.1002/ajh.24536
  • S CHAROENFUPRASERT ET AL: "Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer", ONCOGENE, vol. 30, no. 33, 14 March 2011 (2011-03-14), pages 3570-3584, XP055444336, ISSN: 0950-9232, DOI: 10.1038/onc.2011.77
  • T. B. SUNDBERG ET AL: "Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 111, no. 34, 11 August 2014 (2014-08-11), pages 12468-12473, XP055444431, US ISSN: 0027-8424, DOI: 10.1073/pnas.1412308111
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).